<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345915</url>
  </required_header>
  <id_info>
    <org_study_id>LEA-JA-IPC 2014-005</org_study_id>
    <nct_id>NCT02345915</nct_id>
  </id_info>
  <brief_title>Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia</brief_title>
  <acronym>LEA-JA</acronym>
  <official_title>Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia-LEA-JA-IPC 2014-005</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aix Marseille Université</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taking into account the specificities of adolescent and young adult cancer patients led
      agencies (in particular the French National Cancer Institute INCa, through the last Cancer
      Plan), to initiate projects targeting this population. Acute leukemia is among the most
      common cancers in adolescents and young adults. Recent therapeutic advances now allow hope
      for a cure in about 50% of this population. The issue of post-cancer is therefore of
      particular importance for young adults with cancer. Our aim is to establish the health
      determinants in young adult leukemia survivors and to compare the frequency of these effects
      and their explanatory factors to the data collected in children or adolescent leukemia
      survivors program (LEA). 90 patients followed up at the Institut Paoli-Calmettes cancer
      center and Nice University Hospital have been identified and would be included in this
      study.Collected data will include information on the initial disease and its treatments,
      physical sequelae (fertility, thyroid function, heart function, visual function, secondary
      tumors, viral infections, lung function, bone metabolism, iron metabolism, metabolic
      syndrome, osteonecrosis, alopecia ... ), quality of life, social and occupational integration
      and relationship with care system.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late sequelae evaluation of young adult acute leukemia-survivors</measure>
    <time_frame>24 mois</time_frame>
    <description>Main measured sequelae on: heart function, thyroid function, visual function, lung function, bone metabolism, secondary tumors, viral infections, iron metabolism, metabolic syndrome, gonadic, fertility, renal function, liver function,…</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality-of-life assessment of young adult acute leukemia-survivors</measure>
    <time_frame>24 mois</time_frame>
    <description>Quality of life questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the frequency of sequelae between children/adolescents (LEA cohort) and young adults acute leukemia survivors (LEA-JA)</measure>
    <time_frame>24 mois</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Young adult acute leukemia-survivor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Young adult acute leukemia-survivor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <arm_group_label>Young adult acute leukemia-survivor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young adult (18-40 years) Leukemia survivor, in complete remission.

          -  Acute leukemia diagnosed since January 1980 .

          -  Patient Affiliated to social security or beneficiary

          -  Signed Informed Consent prior to any screening procedures

        Exclusion Criteria:

          -  Emergency

          -  Patient unable to abide by the study protocol (for geographical, social or
             psychological reasons)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert VEY, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>0033491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane Pakradouni, PharmD PhD</last_name>
    <phone>0033491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Genre, MD</last_name>
      <phone>0033491223778</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert VEY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

